Results 181 to 190 of about 34,135 (204)

Olaparib

Reactions Weekly, 2018
Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single ...
Sylvia, Bochum, Stephanie, Berger, Uwe M, Martens   +2 more
  +5 more sources

Olaparib

Reactions Weekly, 2023
  +10 more sources

Olaparib

Reactions Weekly, 2022
  +5 more sources

Olaparib

Reactions Weekly, 2020
  +5 more sources

Olaparib

Reactions Weekly, 2019
  +5 more sources

Adjuvant olaparib — should all patients with breast cancer have genetic testing?

Nature Reviews Clinical Oncology, 2021
Steven A Narod
exaly  

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2020
Maha H A Hussain, Joaquin Mateo, Fred Saad   +2 more
exaly  

Olaparib for Metastatic Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2020
Johann Sebastian de Bono, Joaquin Mateo, Fred Saad   +2 more
exaly  

Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?

Nature Reviews Clinical Oncology, 2020
Emmanuel S Antonarakis Mbbch
exaly  

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

New England Journal of Medicine, 2019
Isabelle Ray-Coquard, Sandro Pignata, Keiichi Fujiwara   +2 more
exaly